Perspective: Cardiovascular disease in the postgenomic era - Lessons learned and challenges ahead

Endocrinology

Volumn 143, Issue 6, 2002, Pages 2045-2050

  Epstein, Jonathan A ^a   Rader, Daniel J ^a   S parmacek, Michael ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONFERENCE PAPER; CONGENITAL HEART DISEASE; GENE MAPPING; GENETIC ASSOCIATION; GENOMICS; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HUMAN GENOME; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPOPROTEIN METABOLISM; MONOGENIC DISORDER; PATHOGENESIS; PRIORITY JOURNAL; UNITED STATES;

EID: 0036093384     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.143.6.8910     Document Type: Conference Paper

References (58)

1. Shattuck lecture-cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities
2. A receptor-mediated pathway for cholesterol homeostasis
3. Statin trials and goals of cholesterol-lowering therapy
4. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population
5. The management of hypertrophic cardiomyopathy
6. Cardiovascular risks to young persons on the athletic field
7. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy
8. The failing heart
9. Idiopathic dilated cardiomyopathy
10. The genetics of dilated cardiomyopathy - Emerging clues to the puzzle
11. The cellular basis of dilated cardiomyopathy in humans
12. Dystrophies and heart disease
13. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy
14. Cytoplasmic signaling pathways that regulate cardiac hypertrophy
15. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo
16. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5
17. Transcriptional regulation of cardiac development: Implications for congenital heart disease and DiGeorge syndrome
18. The genetic basis of paediatric heart disease
19. A genetic blueprint for cardiac development
20. Genetic assembly of the heart: Implications for congenital heart disease
21. Congenital heart disease caused by mutations in the transcription factor NKX2-5
22. Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways
23. NKX2.5 mutations in patients with tetralogy of fallot
24. Developing models of DiGeorge syndrome
25. Deconstructing DiGeorge syndrome
26. Frequency of 22q11 deletions in patients with conotruncal defects
27. Association of chromosome 22q11 deletion with isolated anomalies of aortic arch laterality and branching
28. Congenital heart disease in mice deficient for the DiGeorge syndrome region
29. Tbx1 haploinsufficieny in the DiGeorge syndrome region causes aortic arch defects in mice
30. TBX1 is responsible for cardiovascular defects in velo-cardio- facial/DiGeorge syndrome
31. DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1
32. Mutation analysis of TBX1 in non-deleted patients with features of DGS/VCFS or isolated cardiovascular defects
33. Mutations in human TBX5 cause limb and cardiac malformation in Holt-Oram syndrome
34. Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome
35. A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease
36. Inherited duplication, dup (8) (p23.1p23.1) pat, in a father and daughter with congenital heart defects
37. Genetic susceptibility to death from coronary heart disease in a study of twins
38. Family history of heart attack as an independent predictor of death due to cardiovascular disease
39. Genetic polymorphisms, lipoproteins and coronary artery disease risk
40. High-density lipoprotein - The clinical implications of recent studies
41. Familial hypoalphalipoproteinemia in premature coronary artery disease
42. Familial hyper-α-lipoproteinemia: Studies in eighteen kindreds
43. Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models
44. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis
45. Molecular mechanisms of reverse cholesterol transport
46. Pathophysiology of reverse cholesterol transport. Insights from inherited disorders of lipoprotein metabolism
47. Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease
48. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes
49. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1
50. The molecular pathology of lecithin: Cholesterol acyltransferase (LCAT) deficiency syndromes
51. Disruption of the murine lecithin: Cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I
52. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation
53. Genetics and molecular biology of hepatic lipase
54. Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics
55. Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice
56. Linkage of high-density lipoprotein-cholesterol concentrations to a locus on chromosome 9p in Mexican Americans